-
公开(公告)号：US09206234B2
公开(公告)日：2015-12-08
申请号：US14340231
申请日：2014-07-24
Applicant: BAXTER INTERNATIONAL INC. , BAXTER HEALTHCARE SA
Inventor： Friedrich Scheiflinger , Michael Dockal
IPC: C07K7/08 , C07K7/06 , C07K14/755
Abstract: The invention provides a method of making a peptide comprising the amino acid sequence WDLYFEIVW (SEQ ID NO: 322) or a variant thereof, the method comprising (a) coupling the C-terminal amino acid of the peptide to a cleavable linking moiety bonded to a solid phase support material, wherein the alpha-amino group of the C-terminal amino acid that is to be coupled bears an Fmoc protecting group; (b) removing the Fmoc protecting group from the C-terminal amino acid that is coupled to the linking moiety; (c) successively coupling Fmoc-protected amino acids to the C-terminal amino acid, with attendant cleavage of the Fmoc protecting group prior to each successive amino acid addition, thereby producing an amino acid sequence bearing side chain protecting groups; and (d) removing the side chain protecting groups and cleaving the peptide from the solid phase support material.
Abstract translation: 本发明提供了制备包含氨基酸序列WDLYFEIVW（SEQ ID NO：322）或其变体的肽的方法，所述方法包括（a）将肽的C-末端氨基酸与可键合到 固相载体材料，其中待偶联的C端氨基酸的α-氨基具有Fmoc保护基; （b）从与所述连接部分偶联的C末端氨基酸中除去Fmoc保护基团; （c）连续将Fmoc保护的氨基酸偶联至C-末端氨基酸，并在每次连续的氨基酸加入之前伴随着Fmoc保护基裂解，由此产生带有侧链保护基团的氨基酸序列; 和（d）除去侧链保护基团并从固相载体材料中切割肽。
-
公开(公告)号：US20150232514A1
公开(公告)日：2015-08-20
申请号：US14677581
申请日：2015-04-02
Applicant: BAXTER INTERNATIONAL INC. , BAXTER HEALTHCARE SA
Inventor： Michael Dockal , Rudolf Hartmann , Markus Fries , Friedrich Scheiflinger , Hartmut Ehrlich , Ulrich Reineke , Frank Osterkamp , Thomas Polakowski
CPC classification number: A61K38/10 , A61K38/00 , A61K2121/00 , C07K1/14 , C07K7/08 , C07K14/00 , C07K14/8114 , G01N33/68 , G01N2333/745 , G01N2333/8114 , G01N2333/96444 , G01N2333/96447 , G01N2500/02 , G01N2500/04 , G01N2500/20 , G06F19/16 , G06F19/18
Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
Abstract translation: 本发明提供了结合组织因子途径抑制剂（TFPI），包括TFPI抑制肽的肽及其组合物。 肽可以用于抑制TFPI，增强凝血因子缺陷受试者中的凝血酶形成，增加受试者中的血块形成，治疗受试者的血液凝固障碍，纯化TFPI和鉴定TFPI结合化合物。
-
公开(公告)号：US08962563B2
公开(公告)日：2015-02-24
申请号：US13756036
申请日：2013-01-31
Applicant: Baxter International Inc. , Baxter Healthcare SA
Inventor： Michael Dockal , Rudolf Hartmann , Friedrich Scheiflinger , Frank Osterkamp , Thomas Polakowski , Ulrich Reineke
CPC classification number: C07K14/001 , A61K38/00 , C07K7/08 , C07K14/435 , G01N33/86 , G01N2500/04 , G01N2500/20
Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
Abstract translation: 本发明提供了结合组织因子途径抑制剂（TFPI），包括TFPI抑制肽的肽及其组合物。 还提供肽复合物。 肽可以用于抑制TFPI，增强凝血因子缺陷受试者中的凝血酶形成，增加受试者中的血块形成，治疗受试者的血液凝固障碍，纯化TFPI和鉴定TFPI结合化合物。
-
公开(公告)号：US09556230B2
公开(公告)日：2017-01-31
申请号：US14677581
申请日：2015-04-02
Applicant: BAXTER INTERNATIONAL INC. , BAXTER HEALTHCARE SA
Inventor： Michael Dockal , Rudolf Hartmann , Markus Fries , Friedrich Scheiflinger , Hartmut Ehrlich , Ulrich Reineke , Frank Osterkamp , Thomas Polakowski
CPC classification number: A61K38/10 , A61K38/00 , A61K2121/00 , C07K1/14 , C07K7/08 , C07K14/00 , C07K14/8114 , G01N33/68 , G01N2333/745 , G01N2333/8114 , G01N2333/96444 , G01N2333/96447 , G01N2500/02 , G01N2500/04 , G01N2500/20 , G06F19/16 , G06F19/18
Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
Abstract translation: 本发明提供了结合组织因子途径抑制剂（TFPI），包括TFPI抑制肽的肽及其组合物。 肽可以用于抑制TFPI，增强凝血因子缺陷受试者中的凝血酶形成，增加受试者中的血块形成，治疗受试者的血液凝固障碍，纯化TFPI和鉴定TFPI结合化合物。
-
公开(公告)号：US20130259863A1
公开(公告)日：2013-10-03
申请号：US13846359
申请日：2013-03-18
Applicant: BAXTER HEALTHCARE SA , Baxter International Inc.
Inventor： Michael Dockal , Rudolf Hartmann , Markus Fries , Friedrich Scheiflinger , Hartmut Ehrlich , Ulrich Reineke , Frank Osterkamp , Thomas Polakowski
IPC: C07K14/00
CPC classification number: A61K38/10 , A61K38/00 , A61K2121/00 , C07K1/14 , C07K7/08 , C07K14/00 , C07K14/8114 , G01N33/68 , G01N2333/745 , G01N2333/8114 , G01N2333/96444 , G01N2333/96447 , G01N2500/02 , G01N2500/04 , G01N2500/20 , G06F19/16 , G06F19/18
Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
-
Patent Agency Ranking
6.发明申请COMPOSITIONS OF HUMAN PROTHROMBIN AND ACTIVATED FACTOR X FOR IMPROVING HEMOSTASIS IN THE TREATMENT OF BLEEDING DISORDERS 审中-公开人类丙种球蛋白和激活因子X的组合物，用于改善治疗失血性疾病的HEMOSTASIS公开(公告)号：US20150258182A1
公开(公告)日：2015-09-17
申请号：US14658006
申请日：2015-03-13
Applicant: BAXTER INTERNATIONAL INC. , BAXTER HEALTHCARE SA
Inventor： Michael Dockal , Sabine Knappe , Susanne Till , Friedrich Scheiflinger , Peter Leopold Turecek
IPC: A61K38/48
CPC classification number: A61K38/4833 , A61K38/4846 , A61K38/54 , C12Y304/21005 , C12Y304/21006
Abstract: Disclosed herein are compositions and methods for improving hemostasis in the treatment of bleeding disorders and reversal of anticoagulant activity. Effective ratios of prothrombin (FII) and activated factor X (FXa) for the treatment of bleeding disorders that are as efficacious as FEIBA®, but require a lower concentration of FII are described herein.
Abstract translation: 本文公开了用于改善止血治疗出血性疾病和逆转抗凝活性的组合物和方法。 本文描述了治疗与FEIBA®有效但需要较低FII浓度的出血性疾病有关的凝血酶原（FII）和活化因子X（FXa）的有效比例。
-
公开(公告)号：US20150246947A1
公开(公告)日：2015-09-03
申请号：US14634028
申请日：2015-02-27
Applicant: BAXTER INTERNATIONAL INC. , BAXTER HEALTHCARE SA
Inventor： Michael Dockal , Thomas Polakowski , Frank Osterkamp , Rudolf Hartmann , Matthias Paschke , Bettina Hartlieb , Friedrich Scheiflinger
CPC classification number: A61K38/10 , A61K38/00 , A61K47/60 , C07K7/08 , C07K14/745
Abstract: The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.
Abstract translation: 本发明提供肽，包括结合并任选地抑制蛋白S的肽及其组合物。 肽可以用于例如抑制蛋白S活性，增强受试者中的凝血酶形成，增加受试者中的血块形成，治疗受试者的血液凝固障碍，纯化蛋白S，并鉴定蛋白S结合化合物。
-
公开(公告)号：US09018167B2
公开(公告)日：2015-04-28
申请号：US13846359
申请日：2013-03-18
Applicant: Baxter International Inc. , Baxter Healthcare SA
Inventor： Michael Dockal , Rudolf Hartmann , Markus Fries , Friedrich Scheiflinger , Hartmut Ehrlich , Ulrich Reineke , Frank Osterkamp , Thomas Polakowski
CPC classification number: A61K38/10 , A61K38/00 , A61K2121/00 , C07K1/14 , C07K7/08 , C07K14/00 , C07K14/8114 , G01N33/68 , G01N2333/745 , G01N2333/8114 , G01N2333/96444 , G01N2333/96447 , G01N2500/02 , G01N2500/04 , G01N2500/20 , G06F19/16 , G06F19/18
Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
Abstract translation: 本发明提供了结合组织因子途径抑制剂（TFPI），包括TFPI抑制肽的肽及其组合物。 肽可以用于抑制TFPI，增强凝血因子缺陷受试者中的凝血酶形成，增加受试者中的血块形成，治疗受试者的血液凝固障碍，纯化TFPI和鉴定TFPI结合化合物。
-
公开(公告)号：US20130252896A1
公开(公告)日：2013-09-26
申请号：US13756036
申请日：2013-01-31
Applicant: BAXTER INTERNATIONAL INC. , BAXTER HEALTHCARE SA
Inventor： Michael Dockal , Rudolf Hartmann , Friedrich Scheiflinger , Frank Osterkamp , Thomas Polakowski , Ulrich Reineke
IPC: C07K14/00
CPC classification number: C07K14/001 , A61K38/00 , C07K7/08 , C07K14/435 , G01N33/86 , G01N2500/04 , G01N2500/20
Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
Abstract translation: 本发明提供了结合组织因子途径抑制剂（TFPI），包括TFPI抑制肽的肽及其组合物。 还提供肽复合物。 肽可以用于抑制TFPI，增强凝血因子缺陷受试者中的凝血酶形成，增加受试者中的血块形成，治疗受试者的血液凝固障碍，纯化TFPI和鉴定TFPI结合化合物。
-
公开(公告)号：US09447147B2
公开(公告)日：2016-09-20
申请号：US14634028
申请日：2015-02-27
Applicant: BAXTER INTERNATIONAL INC. , BAXTER HEALTHCARE SA
Inventor： Michael Dockal , Thomas Polakowski , Frank Osterkamp , Rudolf Hartmann , Matthias Paschke , Bettina Hartlieb , Friedrich Scheiflinger
IPC: C07K7/08 , A61K38/10 , A61K47/48 , C07K14/745 , A61K38/00
CPC classification number: A61K38/10 , A61K38/00 , A61K47/60 , C07K7/08 , C07K14/745
Abstract: The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.
Abstract translation: 本发明提供肽，包括结合并任选地抑制蛋白S的肽及其组合物。 肽可以用于例如抑制蛋白S活性，增强受试者中的凝血酶形成，增加受试者中的血块形成，治疗受试者的血液凝固障碍，纯化蛋白S，并鉴定蛋白S结合化合物。
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.029 seconds)
